In a proof of concept study, patients are treated with the histone deacetylase inhibitor vorinostat for 14 days upon resistance and thereafter BRAF and/or MEK inhibitors are reintroduced.27 This cohort contains unique data on paired molecular analyses in tumour tissue for patients with BRAFV600E mutant metastatic CRC treated with encorafenib and cetuximab with or without binimetinib or alpelisib. The gene discussed is BRAF; the disease is neoplasm.